BioMarin Pharmaceuticals
BMRN
430 hedge funds and large institutions have $14.6B invested in BioMarin Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 147 increasing their positions, 158 reducing their positions, and 53 closing their positions.
1.29% more ownership
Funds ownership: 101.12% → 102.41% (+1.3%)
7% less repeat investments, than reductions
Existing positions increased: 147 | Existing positions reduced: 158
8% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 53
2% less funds holding
Funds holding: 438 → 430 (-8)
8% less capital invested
Capital invested by funds: $15.8B → $14.6B (-$1.2B)
22% less call options, than puts
Call options by funds: $76.6M | Put options by funds: $97.9M
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$302M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$144M |
| 3 |
HCM
Highline Capital Management
New York
|
+$109M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$89.7M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$74.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$157M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$80.6M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$61.2M |
| 4 |
JP Morgan Chase
New York
|
-$45.3M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
-$41.1M |
BMRN Hedge Fund Activity: Q1 2018 in Review
430 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2018, worth a combined $14.6B — down 7.6% from $15.8B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of BMRN and 49 opened new positions — a net loss of 4 holders — while 158 trimmed existing stakes and 147 added.
The largest buyer was Primecap Management, adding an estimated $302M. The largest seller was Fidelity Investments, cutting an estimated $157M.
- 430 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2018, down from 438 in Q4 2017.
- Funds reported $14.6B of BioMarin Pharmaceuticals stock for Q1 2018, down 7.6% quarter-over-quarter.
- 49 funds opened new BioMarin Pharmaceuticals positions in Q1 2018 and 53 closed out, a net change of -4 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2018 was Primecap Management, an estimated $302M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2018 was Fidelity Investments, an estimated $157M sold.
Based on aggregated 13F filings for Q1 2018.